Headlines

Camp Lejeune status fall 2025: latest developments on CLJA lawsuits and the settlement progress.

The ruling establishes that public nuisance claims can be applied to hold defendants accountable for opioid distribution in West Virginia. This is a significant shift in legal strategy.

Learn about the warning letters the U.S. FDA issued to Novo Nordisk and Eli Lilly regarding false or misleading claims about the safety of GLP-1 drugs.

Research has linked certain birth control drugs to brain tumors. Learn which drugs might increase your risks.

There’s a dark side to semaglutide. It includes high medication costs, drug shortages and severe side effects.

The August 28, 2025, ruling by U.S. District Judge George Daniels found that the plaintiffs’ claims were sufficiently strong to proceed and rejected the Kingdom of Saudi Arabia argument that its alleged ties to the attackers were coincidental and innocent.

Motley Rice member Mike Daly was appointed to the Board of Directors for the Philadelphia Trial Lawyers Association (PTLA).

Motley Rice LLC welcomed nine talented law students all representing different law schools for its 2025 summer law clerk program.

Glyphosate bans have been enacted in several U.S. cities and foreign countries due to health concerns.

Motley Rice welcomes Joshua M. Neuman as senior counsel and Josey M. Richards and Alexandra A. Stulpin joined as associates at Three Logan Square in Philadelphia.